Pharmacokinetics of itraconazole after intravenous and oral dosing of itraconazole-cyclodextrin formulations

Journal of Pharmaceutical Sciences

Volumn 96, Issue 11, 2007, Pages 3100-3116

  Buchanan, Charles M ^a   Buchanan, Norma L ^a   Edgar, Kevin J ^a   Klein, Sandra ^b   Little, James L ^a   Ramsey, Michael G ^a   Ruble, Karen M ^a   Wacher, Vincent J ^a   Wempe, Michael F ^a  

^a EASTMAN CHEMICAL COMPANY   (United States)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

Bioavailability; Food; Formulations; Hydroxybutenyl cyclodextrin; Hydroxyitraconazole; Hydroxypropyl cyclodextrin; Itraconazole; Pharmacokinetics

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; CYCLODEXTRIN; HYDROXYBUTENYL BETA CYCLODEXTRIN; HYDROXYITRACONAZOLE; ITRACONAZOLE; MACROGOL 400; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG METABOLISM; DRUG SOLUBILITY; DRUG STRUCTURE; FOOD; MALE; NONHUMAN; RAT;

EID: 36848999855     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20878     Document Type: Article

References (49)

1. Cleary JD, Taylor JW, Chapman SW. 1992. Itraconazole in antifungal therapy. Ann Pharmacother 26:502-509.
2. De Doncker P, Decroix J, Pierard GE, Roelant D, Woestenborghs R, Jacqmin P, Odds F, Heremans A, Dockx P, Roseeuw D. 1996. Antifungal pulse therapy for onychomycosis. A pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole. Arch Dermatol 132:34-41.
3. Denning DW, Tucker RM, Hanson LH, Stevens DA. 1989. Treatment of invasive aspergillosis with itraconazole. Am J Med 86:791-800.
4. Lyman CA, Walsh TJ. 1992. Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications. Drugs 44:9-35.
5. Wheat J, Hafner R, Korzun AH, Limjoco MT, Spencer P, Larsen RA, Hecht FM, Powderly W. 1995. Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trial Group. Am J Med 98:336-342.
6. Barone JA, Moskovitz BL, Guarnieri J, Hassell AE, Colaizzi JL, Bierman RH, Jessen L. 1998. Enhanced bioavailability of itraconazole in hydroxypropyl-β-cyclodextrin solution versus capsules in healthy volunteers. Antimicrob Agents Chemother 42:1862-1865.
7. Willems L, van der Geest R, de Beule K. 2001. Itraconazole oral solution and intravenous formulations: A review of pharmacokinetics and pharmacodynamics. J Clin Pharm Ther 26:159-169.
8. Sporanox® product label. www.fda.gov.
9. Okamoto Y, Hirano M, Kondo A, Miyake K, Irie T, Hirayama F, Uekama K. 1999. Characterization of itraconazole/2-hydroxypropyl-β-cyclodextrin inclusion complex in aqueous solution. Int J Pharm 179:237-245.
10. Peeters J, Neeskens P, Van Remoortere P, Brewster ME. 2000. Curve fitting algorithms for determining higher order complexation constants: Application to HPBCD-based formulation of Sporanox. Proceedings of the international symposium on cyclodextrins, 10th. Szejtli J, editor.
11. Chowdary KPR, Shaik SR. 2003. Studies on complexation of itraconazole with α, β, γ and hydroxypropyl-β-cyclodextrins. Indian Drugs 39:133-137.
12. Chowdary KPR, Rao Srinivasa SK. 2001. Formulation and evaluation of complexes of itraconazole with β-cyclodextrin and their tablets. Int J Pharm Excipients 3:84-88.
13. Peeters J, Neeskens P, Tollenaere JP, Van Remoortere P, Brewster ME. 2002. Characterization of the interaction of 2-hydroxypropyl-β-cyclodextrin with itraconazole at pH 2, 4, and 7. J Pharm Sci 91:1414-1422.
14. Connors KA. 1997. The stability of cyclodextrin complexes in solution. Chem Rev 97:1325-1357.
15. Szejtli J. 1995. Selectivity/structure correlation in cyclodextrin chemistry. Supramol Chem 6:217-223.
16. Uekama K, Hirayama F, Irie T. 1998. Cyclodextrin drug carrier systems. Chem Rev 98:2045-2076.
17. Szejtli J. 1991. Cyclodextrins in drug formulations: Part II. Pharm Technol 15:24-38.
18. De Beule K. 1996. Itraconazole: Pharmacology, clinical experience and future development. Int J Antimicrob Agents 6:175-181.
19. Shin JH, Choi KY, Kim YC, Lee MG. 2004. Dose-dependent pharmacokinetics of itraconazole after intravenous or oral administration to rats: Intestinal first-pass effect. Antimicrob Agents Chemother 48:1756-1762.
20. Hostetler JS, Hanson LH, Stevens DA. 1992. Effect of cyclodextrin on the pharmacology of antifungal oral azoles. Antimicrob Agents Chemother 36:477-480.
21. Lee AK, Ahn CY, Kim EJ, Kwon JW, Kim SG, Chung SJ, Shim CK, Lee MG. 2003. Effects of cysteine on the pharmacokinetics of itraconazole in rats with protein-calorie malnutrition. Biopharm Drug Dispos 24:63-70.
22. Yoo SD, Lee SH, Kang E, Jun H, Jung JY, Park JW, Lee KH. 2000. Bioavailability of itraconazole in rats and rabbits after administration of tablets containing solid dispersion particles. Drug Dev Ind Pharm 26:27-34.
23. Yao M, Chen L, Srinivas NR. 2001. Quantization of itraconazole in rat heparinized plasma by liquid chromatography-mass spectrometry. J Chromatogr B 752:9-16.
24. Shin JH, Choi KY, Kim YC, Lee MG. 2004. Dose-dependent pharmacokinetics of itraconazole after intravenous or oral administration to rats: Intestinal first-pass effect. Antimicrob Agents Chemother 48:1756-1762.
25. Koks CHW, Meenhorst PL, Bult A, Beijnen JH. 2002. Itraconazole solution: Summary of pharmacokinetic features and review of activity in the treatment of fluconazole-resistant oral candidosis in HIV-infected persons. Pharmacol Res 46:195-201.
26. Buchanan CM, Alderson SR, Cleven CD, Dixon DW, Ivanyi R, Lambert JL, Lowman DW, Offerman RJ, Szejtli J, Szente L. 2002. Synthesis and characterization of water-soluble hydroxybutenyl cyclodextrins. Carbohydr Res 327:493-507.
27. Klein S. 2005. Biorelevant dissolution test methods for modified release dosage forms, in institut für pharmazeutische technologie. Johann Wolfgang Goethe-Universität: Frankfurt. ISBN 3-8322-4276-7.
28. Food and Drug Administration. 2000. Guidance for industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER): Rockville MD, USA.
29. Marques M. 2004. Dissolution media simulating fasted and fed states. Dissolution Technol 16.
30. Russell TL, Berardi RR, Barnett JL, O'Sullivan TL, Wagner JG, Dressman JB. 1994. pH-related changes in the absorption of dipyridamole in the elderly. Pharma Res 11:136-143.
31. Chen TM, Shen H, Zhu C. 2002. Evaluation of a method for high throughput solubility determination using a multi-wavelength UV plate reader. Comb Chem High Throughput Screen 5: 575-581.
32. Pan L, Ho Q, Tsutsui K, Takahashi L. 2001. Comparison of chromatographic and spectroscopic methods used to rank compounds for aqueous solubility. J Pharma Sci 90:521-529.
33. Hostetier JS, Hanson LH, Stevens DA. 1993. Effect of hydroxy-β- cyclodextrin on oral efficacy of oral itraconazole in disseminated murine cryptococcosis. J Antimicrob Chemother 32:459-463.
34. Miyake K, Irie T, Arima H, Hirayama F, Uekama K, Hirano M, Okamoto Y. 1999. Characterization of itraconazole/2-hydroxypropyl-B-cyclodextrin inclusion complex in aqueous solution. Int J Pharm 179:237-245.
35. USP 28-NF 23 711. 2005. The United States pharmacopoeial convention, Canada: Inc., Webcom Limited. 2412-2414.
36. Klein S, Dressman JB. 2006. The mini paddle apparatus - A useful tool in the early developmental stage? Experiences with an immediate release dosage form. 33rd Annual Meeting & Exposition of the Controlled Release Society. Vienna, Austria.
37. WHO. 2005. Proposal to waive in vivo bioequivalence requirements for the WHO model list of essential medicines immediate release, solid oral dosage forms, working document QAS/04.109/Rev. 1. Geneva: World Health Organisation.
38. Stippler E. 2004. Biorelevant dissolution test methods to asses bioequivalence of drug products, institute of pharmaceutical technology. Frankfurt: Johann Wolfgang Goethe University.
39. Little J, Wempe M, Buchanan C. 2006. A novel approach for probing lipid matrix ionization effects in pharmacokinetic studies of protein precipitated blood plasma employing positive ion electrospray LC-MS/MS. J Chromatogr B 833:219-230.
40. Yang L, Wu N, Clement RP, Rudewicz PJ. 2004. Validation and application of a liquid chromatography-tandem mass spectrometric method for the determination of SCH 211803 in rat and monkey plasma using automated 96-well protein precipitation. J Chromatogr B 799:271-280.
41. Liang H, Bennet P. 2003. Suppression in electrospray ionization between target drugs and stable-isotope-labeled internal standards in quantitative liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 17:2815-2821.
42. Mei H. 2005. Matrix effects: Causes and solutions. In: Korfmacher W, editor. Using mass spectrometry for drug metabolism studies, 1st edition. Philadelphia: CRC Press. pp 103-150.
43. Food and Drug Administration. 2001. Guidance for industry bioanalytical method validation. http://www.fda.gov/cder/guidance/4252fnl.pdf U.S. Department of Health and Human Service, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Veterinary Medicine.
44. Rowland M, Tozer TN. 1995. Clinical pharmacokinetics, 3rd edition (January 15, 1995). PA: Lippincott, Williams, & Wilkins.
45. Buchanan CM, Buchanan NL, Edgar KJ, Lambert JL, Posey-Dowty JD, Ramsey MG, Wempe MF. 2006. Solubilization and dissolution of tamoxifen-hydroxybutenyl cyclodextrin complexes. J Pharma Sci 95:2246-2255.
46. The mean AUC, standard deviations, and the number of plasma samples for these groups are given in the supplementary material section.
47. Zhou H, Goldman M, Wu J, Woestenborghs R, Hassell AE, Lee P, Baruch A, Pesco-Koplowitz L, Borum J, Wheat LJ. 1998. A pharmacokinetic study of intravenous itraconazole followed by oral administration of itraconazole capsules in patients with advanced human immunodeficiency virus infection. J Clin Pharm 38:593-602.
48. Szejtli J. 2005. Cyclodextrin complexed generic drugs are generally not bio-equivalent with the reference products: Therefore the increase in number of marketed drug/cyclodextrin formulations is so slow. J Inclusion Phenomena and Macrocyclic Chem 52:1-11.
49. Buchanan CM, Buchanan NL, Edgar KJ, Little JL, Malcolm MO, Ruble KM, Wacher VJ, Wempe MF. 2007. Pharmacokinetics of tamoxifen after intravenous and oral dosing of tamoxifen-hydroxybutenyl-β-cyclodextrin formulations. J Pharma Sci 96:644-660.